INTRODUCTION
The 5-year overall survival of children with newly diagnosed acute lymphoblastic leukemia (ALL) exceeds 90% with multi-agent chemotherapy. [1] [2] [3] [4] [5] [6] However, a subset of patients remains at very high-risk (VHR) for relapse and includes older patients and patients with unfavorable cytogenetics, a poor initial response to therapy, and/or central nervous system leukemia. Although targeted therapy has proven effective for patients with Philadelphia chromosome-positive ALL, 7, 8 many patients lack an actionable target. 9, 10 Intensification of conventional chemotherapy has remained the main therapeutic option and has proven effective, but the outcome for VHR patients is still inferior. [11] [12] [13] Thus, the integration of new agents is an attractive option.
Clofarabine is a second-generation purine nucleoside analogue designed to improve anticancer activity and decrease the toxicity associated with the earlier purine nucleoside analogues cladribine and fludarabine.
14 Clofarabine has 3 main mechanisms of action: 1) incorporation into DNA, 2) inhibition of ribonucleotide reductase, and 3) induction of apoptosis. In 2004, the US Food and Drug Administration approved the use of clofarabine for use in pediatric patients 1 to 21 years old with relapsed or refractory ALL after at least 2 prior regimens on the basis of a 30% response rate seen with single-agent therapy at 52 mg/m 2 /d 3 5. 15 Two subsequent studies evaluating the combination of clofarabine, cyclophosphamide, and etoposide in relapsed or refractory ALL demonstrated response rates of 44% 16 and 56%. 17 Because of the encouraging outcomes for children with relapsed or refractory B acute lymphoblastic leukemia (B-ALL) after the administration of clofarabine in combination with cyclophosphamide and etoposide, the Children's Oncology Group AALL1131 study randomized patients with newly diagnosed VHR B-ALL into 3 treatment groups: a control arm, experimental arm 1 (including the combination of cyclophosphamide and etoposide), and experimental arm 2 (including the combination of cyclophosphamide, etoposide, and clofarabine). The safety and efficacy of the 2 experimental arms were evaluated against those of the control arm. This report summarizes the toxicities that led to the closure of experimental arm 2.
MATERIALS AND METHODS

Patients
AALL1131 is a phase 3 study for children and young adults 1 to <31 years old with newly diagnosed B-ALL. Patients eligible at diagnosis were 1) 1 to 9 years old with a white blood cell count (WBC) 50,000/lL, 2) 10 to <31 years old with any WBC, or 3) 1 to <31 years old with testicular leukemia, central nervous system 3 (CNS3) leukemia, or steroid pretreatment (for patients < 10 years old for whom no presteroid WBC was obtained). CNS3 was defined as a WBC 5/lL and cytospins positive for blasts in the cerebral spinal fluid and/or clinical signs of central nervous system leukemia.
At the end of induction therapy, patients were eligible for randomization on the VHR stratum if any of these were found: age 13 years or CNS3 at the initial diagnosis, day 29 bone marrow minimal residual disease 0.01% as measured by flow cytometry at 1 of 2 central reference laboratories, 18 induction failure (>25% blasts in the bone marrow [M3] on day 29), intrachromosomal amplification of chromosome 21 (iAMP21), lysine methyltransferase 2A (KMT2A; formerly known as mixedlineage leukemia or MLL) rearrangement, or severe hypodiploidy (<44 chromosomes and/or DNA index < 0.81). In addition, patients with National Cancer Institute standard-risk ALL 19 who were enrolled in AALL0932 were eligible to be randomized after induction on the VHR stratum of AALL1131 if they had iAMP21, KMT2A rearrangement, severe hypodiploidy, or a failure to achieve remission after induction or were without favorable cytogenetics (no ETV6-RUNX1 or double trisomies 4 1 10) and had day 29 bone marrow minimal residual disease 0.01%. Patients with Down syndrome were not eligible for randomization on the VHR stratum because of a lack of available data on safety in this population, which is known to be at risk for excess toxicity from cytotoxic agents. Toxicities were graded with the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0).
The study was approved by the National Cancer Institute and by institutional review boards at the individual Children's Oncology Group member institutions before patient enrollment. Informed consent was obtained from parents or guardians according to Department of Health and Human Services guidelines.
Treatment
Patients enrolled in AALL1131 received a standard 4-drug induction (Table 1) . Patients identified as having VHR B-ALL were randomized 1:2:2 after induction to 1 of 3 arms: 1) a control arm with Children's Oncology Group-modified augmented Berlin-Frankfurt-M€ unster therapy, including cyclophosphamide, cytosine arabinoside, and mercaptopurine (during consolidation) or thioguanine (during delayed intensification) 11 ; 2) experimental arm 1 with cyclophosphamide and etoposide during the second half of consolidation and delayed intensification; or 3) experimental arm 2 with cyclophosphamide, etoposide, and clofarabine during the second half of consolidation and delayed intensification. The remainder of the therapy was identical for the patients in these 3 treatment arms. Patients with testicular leukemia at diagnosis that did not resolve by the end of induction received testicular irradiation (2400 cGy) during consolidation. Patients with CNS3 leukemia received cranial irradiation (1800 cGy) during the first 4 The total duration of treatment was 2 years for females and 3 years for males from the start of interim maintenance 1. Original Article weeks of maintenance. Patients with hepatic dysfunction (direct bilirubin level > 1.5 times the upper limit of normal or alanine aminotransferase level 3 times the upper limit of normal), renal dysfunction (creatinine clearance < 70 mL/min/1.72 m 2 ), cirrhosis, hepatitis B or C, or elevated lipase levels (>2 times the upper limit of normal) were excluded from participation in the VHR stratum. In addition to routine reporting, specific adverse event reporting for the VHR stratum during consolidation part 2 and delayed intensification part 2 included the following: 1) grade 2 or higher infections with an absolute neutrophil count < 500/lL and grade 3 to 5 infections, regardless of the absolute neutrophil count, after day 29 in consolidation and delayed intensification; 2) adverse events resulting in a longer than 14-day delay in starting interim maintenance 1 or 2; 3) grade 3/4 alanine aminotransferase and aspartate aminotransferase, grade 4 amylase and lipase, or grade 3/4 bilirubin elevations that did not return to grade 2 or lower by the time day 43 vincristine and asparaginase were scheduled to be administered during consolidation or delayed intensification; 4) other nonhematologic grade 3/4 toxicities that did not return to grade 2 or lower by the time day 43 vincristine and asparaginase were scheduled to be administered during consolidation or delayed intensification; 5) grade 3/4 pancreatitis; 6) grade 3/4 capillary leak syndrome; 7) grade 3/4 acute kidney injury; 8) other grade 3 or 4 adverse events attributable to clofarabine; and 9) sinusoidal obstruction syndrome.
AALL1131 opened to accrual in February 2012. However, the VHR arms were temporarily closed to accrual 7 months later (September 2012) because of excessive infectious toxicities observed in experimental arm 2. The study was amended to reduce the dose of clofarabine from 30 to 20 mg/m 2 /d 3 5 and to provide enhanced supportive-care recommendations. Myeloid growth factor (granulocyte colony-stimulating factor [G-CSF] at 5 lg/ kg/dose) was required from 24 hours after the last dose of clofarabine until neutrophil count recovery (absolute neutrophil count 750/lL on 2 consecutive days after the nadir). In addition, supportive-care recommendations during consolidation part 2 and delayed intensification part 2 for patients enrolled in experimental arm 2 included the following: 1) hospitalization until evidence of count recovery, 2) empirical coverage for both grampositive and gram-negative organisms at the onset of fever, and 3) antifungal prophylaxis and/or empiric antifungal therapy for patients with neutropenia on broad-spectrum antibiotics after either 3 to 5 days of persistent fever or recurrence of fever. The VHR arms were reopened in December 2013 and then temporarily closed to accrual in May 2014 for a planned safety analysis. Experimental arm 2 did not reopen and was permanently closed to accrual in September 2014 because of excessive toxicity. 
Statistical Considerations
Patients who were classified as VHR in studies AALL0932 and AALL1131 were eligible for the VHR postinduction randomization in this study. A total of 135 eligible patients were randomized to the 3 arms from study activation to first temporary closure (February 27, 2012, to September 13, 2012; Fig. 1 ). A total of 115 eligible patients were randomized to the 3 arms after accrual was restarted with the reduced dose of clofarabine (November 25, 2013, to May 5, 2014; Fig. 2 ). Study data current as of June 30, 2015 , are included in this report. Proportions of adverse events on the regimens were compared with the chi-square test or Fisher's exact test. All analyses were performed with SAS software (version 9.4; SAS Institute, Cary, North Carolina).
RESULTS
VHR Strata (February 2012 to September 2012)
From February 21, 2012, to September 14, 2012, when the study was suspended because of excessive toxicities, 135 eligible patients were randomized after induction to the VHR arms of AALL1131. No patient had reached delayed intensification part 2 at the time of the study's suspension. Table 2 lists protocol targeted toxicities among the 128 patients who entered consolidation part 2 (control arm [n 5 25], experimental arm 1 [n 5 51], and experimental arm 2 [n 5 52]). Significant differences among the 3 arms included the incidence of grade 4/5 infections and grade 3/4 pancreatitis. Twelve of the 52 patients (23.1%) in experimental arm 2 had infectious complications, which included 11 grade 4 complications (defined as life-threatening consequences with urgent intervention indicated) and 1 grade 5 complication (death), whereas 1 of 51 patients (2%) and 1 of 25 patients (4%) had grade 4 infectious complications in experimental arm 1 and the control arm, respectively (P 5 .0013). Infectious complications began in experimental arm 2 a mean of 11.1 6 2.9 days after the start of consolidation part 2. Six of the 52 patients (11.5%) in experimental arm 2 had grade 3/4 pancreatitis, whereas none of the patients in experimental arm 1 or the control arm did (P 5 .0142).
Comparisons between experimental arm 2 and the control arm and between experimental arms 2 and 1 were conducted for each targeted toxicity (Table 2 ). Grade 4 and 5 infectious complications remained increased in experimental arm 2 versus the control arm (P 5 .0979) and experimental arm 1 (P 5 .0039).
The microbiologically confirmed pathogens in each of the 3 arms of the VHR strata are shown in Table 3 and included gram-positive, gram-negative, and anaerobic bacterial and fungal organisms. There were more infectious organisms identified in patients in experimental arm 2 (n 5 25) versus the control arm (n 5 2) or experimental arm 1 (n The mean number of days to complete the scheduled 28-day cycle of consolidation part 2 was 40.1 6 8.4, 37.5 6 6.9, and 51.3 6 22.8 for the control arm, experimental arm 1, and experimental arm 2, respectively. This resulted in an increased number of days to complete consolidation part 2 between experimental arm 2 and the control arm (P 5 .057) and between experimental arms 2 and 1 (P 5 .0013). On the basis of the infectious toxicities observed and treatment-related delays, further enrollment in the study was suspended in September 2012, and investigators were instructed not to start any 5-day clofarabine cycle in either consolidation part 2 or delayed intensification part 2 and to omit any additional clofarabine for patients who had already started a 5-day cycle. The VHR arms were reopened to accrual in December 2013 after an amendment to reduce the dose of clofarabine and provide additional supportive-care guidelines. Table 2 . Grade 3/4 elevations of aspartate aminotransferase, alanine aminotransferase, and/or bilirubin that did not return to grade 2 or lower by day 43 of consolidation part 2 were seen in 5 of 46 patients (10.9%) in experimental arm 1 versus none of the patients in experimental arm 2 or the control arm (P 5 .0456). There were no significant differences among the 3 arms for the remaining targeted toxicities.
During consolidation part 2, despite the clofarabine dose reduction and increased supportive-care measures recommended for patients in experimental arm 2, 4 of 39 patients (10.3%) in experimental arm 2 developed grade 4 infectious complications, with 1 of these patients developing a grade 5 toxicity (acute kidney injury) attributed to clofarabine. Infectious complications began in experimental arm 2 a mean of 9.0 6 1.4 days after the start of consolidation part 2. The infections were attributed to viridans group streptococcus, Enterobacter cloacae, and Pseudomonas aeruginosa. This was in contrast to the control arm, in which no grade 4 or higher infections were reported, and experimental arm 1, in which a grade 4 or higher infection was reported for 1 of 46 patients (2.2%). In addition, 4 patients in experimental arm 2 developed prolonged cytopenias for >60 days; they included 1 patient with a grade 5 acute kidney injury who died 92 days after the start of consolidation part 2 and 1 patient requiring removal from protocol therapy because of pancytopenia (also 92 days after the start of consolidation part 2). The blood counts of neither of these 2 patients recovered before day 92. No patient in either the control arm or experimental arm 1 experienced prolonged cytopenias for >60 days.
The mean number of days to complete the scheduled 28-day cycle of consolidation part 2 was 41.3 6 3.8, 37.5 6 8.3, and 42.3 6 14.4 for the control arm, experimental arm 1, and experimental arm 2, respectively. There was no significant difference in the number of days to complete consolidation part 2 between experimental arm 2 and the control arm (P 5 .3515) or between experimental arms 2 and 1 (P 5 .3252).
Thirteen patients reached delayed intensification part 2 and received clofarabine before the closure of experimental arm 2. Three of the 13 patients (23.1%) in experimental arm 2 developed a grade 4 infection with viridans group streptococcus, Streptococcus mitis, and P. aeruginosa. None of the patients who had entered delayed intensification part 2 in the control arm (n 5 8) or experimental arm 1 (n 5 25) developed a grade 4 or 5 infection.
Because of the excessive toxicities observed and prolonged cytopenias despite the reduction in the clofarabine dose, the addition of G-CSF, and other supportive-care measures, experimental arm 2 was permanently closed on September 12, 2014.
DISCUSSION
Experimental arm 2 of AALL1131 was designed to evaluate the safety and efficacy of clofarabine, cyclophosphamide, and etoposide as part of multi-agent chemotherapy for the treatment of children and young adults newly diagnosed with VHR B-ALL. This combination and dosing scheduled had been previously tolerated with an acceptable toxicity profile in similar patients. 17 The starting dose of clofarabine was 30 mg/m Clofarabine was initially studied in a phase 1 study in 25 pediatric patients (age range, 1-19 years; median age, 12 years) with relapsed or refractory leukemia (ALL, n 5 17; acute myeloid leukemia, n 5 8). Most patients were heavily pretreated (1-6 prior regimens), and 9 (36%) had previously received a bone marrow transplant. The maximum tolerated dose as a single agent was 52 mg/m 2 / d 3 5 with dose-limiting toxicities of hepatotoxicity (elevated bilirubin and transaminase levels) that resolved by day 14 and skin rash; no grade 4 or 5 infectious toxicities were reported. Among the 17 patients with ALL treated in the study, there were 4 complete responses and 1 partial response for an overall response rate of 29%. 20 Subsequently, a phase 2 study of single-agent clofarabine (52 mg/m 2 /d 3 5) was conducted in 61 pediatric patients (age range, 1-20 years; median age, 12 years) with relapsed or refractory ALL. Patients again were heavily pretreated (2-6 prior regimens; median, 3 regimens), with 18 (30%) having previously received a bone marrow transplant. Grade 3/4 bilirubin and alanine aminotransferase levels that resolved by day 16 occurred in 16% and 43% of the patients, respectively. Infectious complications (grade 3 or higher) occurred in 69% of the patients, with 15% of the patients developing fungal infections. The overall response rate was 30% (18 of 61), with 7 complete responses, 5 complete responses without platelet recovery, and 6 partial responses. 15 Although infection rates were high, the overall toxicities were deemed tolerable in a heavily pretreated population, and the overall response rate in this patient population was encouraging.
Based on the known synergy between clofarabine and DNA-damaging agents as identified in preclinical studies 21, 22 as well as clinical experience with the combination of cyclophosphamide and etoposide in the treatment of ALL, [23] [24] [25] [26] a phase 1 study was designed to combine all 3 agents. 27 The phase 1 study of clofarabine, cyclophosphamide, and etoposide was conducted in 25 patients (age range, 2-21 years; median age, 9 years) with relapsed or refractory leukemia (ALL, n 5 , and hepatotoxicity (grade 3 or higher) with elevated alanine aminotransferase levels occurred in 38% of the patients. At the final dose level, 1 of 6 patients had prolonged bone marrow aplasia for >42 days. Among the 20 patients with ALL, there were 9 complete responses and 2 complete responses without platelet recovery for a response rate of 55%. 28 Although AALL1131 used a lower dose of clofarabine than this phase 1 study, bone marrow aplasia was again seen in 2 of 39 patients in AALL1131.
On the basis of the results of the aforementioned phase 1 study, a phase 2 study of clofarabine (40 mg/m Patients received 1 to 3 prior regimens (median 2), and 4 had previously received a bone marrow transplant. Of the first 8 patients enrolled, 4 developed severe hepatotoxicity suggestive of sinusoidal obstructive syndrome, which resulted in multiorgan system failure and death for 3 of them. Of the 4 patients with sinusoidal obstructive syndrome, 3 had a concurrent infection, and 3 had previously received a bone marrow transplant. At this point, the study was amended to exclude patients with a prior bone marrow transplant, cirrhosis, viral hepatitis, or elevated conjugated bilirubin levels. Grade 3/4 bilirubin and alanine aminotransferase levels occurred in 28% and 36% of the patients, respectively. Infectious complications (grade 3 or higher) occurred in 76% of the patients, and acute renal failure occurred in 16% of the patients. The response rate was 44% (11 of 25), with 7 complete responses and 4 complete responses without platelet recovery. 16 These results formed the basis for introducing this regimen into the AALL1131 VHR stratum. However, because of the concerns about toxicities with this regimen, the starting dose for clofarabine in More importantly, for 2 of the 39 patients receiving clofarabine, counts failed to recover 92 days after the start of consolidation part 2. One of these patients had a grade 5 acute kidney injury, and the other was removed from protocol therapy. No association with age was seen among the patients with grade 4 or higher infectious toxicities in experimental arm 2, with 43.8% (7 of 16) occurring in patients < 10 years old (range, 1-27 years). The addition of pegaspargase and vincristine to this course of therapy may have contributed to the increased toxicities seen on this study. Prior studies have demonstrated that pegaspargase, when combined with antimetabolite therapy, is associated with increased myelosuppression and infectious complications. 29, 30 Because of the profound toxicities associated with experimental arm 2, it was concluded that the combination of clofarabine, cyclophosphamide, and etoposide, as given on the VHR stratum of AALL1131 for children, adolescents, and young adults with B-ALL, was associated with unacceptable toxicity.
These results highlight the challenge of integrating new chemotherapeutic drugs and novel combinations of cytotoxic agents into the frontline setting, especially in sequence with a standard but already augmented backbone. Even when doses are reduced and supportive care is enhanced, unexpected toxicities may emerge. Alternative new immunotherapeutic approaches, including monoclonal antibodies and antibody conjugates, bispecific T-cell engagers, and chimeric antigen receptor T cells, offer great promise as adjuncts to conventional chemotherapeutic regimens in the frontline setting. However, their integration will also require carefully designed clinical trials to evaluate toxicity and efficacy.
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